Tag: Medicine

Shouriyo Ghosh, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Shouriyo Ghosh, Medicine, Best Innovator Award

Dr. Shouriyo Ghosh: Consultant at Clinical Haematology, Tata Medical Center Kolkata, India

Title/Designation: Dr.
Name: Shouriyo Ghosh
Current Role/Designation: Consultant
Organization/Institution: Clinical Haematology, Tata Medical Center, Kolkata
Country: India
Subject Track: Medicine
Key Areas of Expertise: Haematology and Stem Cell Transplants
Award Category: Best Innovator Award

Dr. Shouriyo Ghosh is a highly accomplished Consultant in Clinical Haematology and Cellular Therapies at Tata Medical Center, Kolkata, India, with broad experience in malignant and non-malignant haematological disorders. His clinical practice encompasses the management of leukemia, lymphoma, myeloma, aplastic anemia, and various bone marrow failure syndromes. He has extensive hands-on expertise in autologous and allogeneic stem cell transplantation, as well as in CAR-T cell therapy for relapsed and refractory B-cell malignancies. Dr. Ghosh’s work integrates cutting-edge laboratory insights with compassionate, evidence-based patient care. Alongside his clinical duties, he is deeply engaged in academic research, teaching, and multicenter collaborations aimed at advancing therapeutic strategies and improving survival outcomes for patients with complex hematologic diseases.

Online Profiles

Google Scholar Profile

Dr. Shouriyo Ghosh’s research impact is reflected through a strong and steadily growing citation record. As per current bibliometric data, his published works have accumulated 155 citations in total, with 127 citations since 2020, indicating significant recent influence in the field of clinical and translational haematology. His h-index of 6 and i10-index of 5 reflect both the productivity and sustained relevance of his scientific contributions across peer-reviewed journals. These metrics highlight his active role in advancing knowledge in hematologic malignancies, stem cell transplantation, and immunotherapy within both national and international research communities.

Education

Dr. Ghosh completed his M.B.B.S. from the University College of Medical Sciences (UCMS), University of Delhi in 2010, where he consistently ranked among the top students and received multiple awards for academic excellence. He pursued his M.D. in Pathology at the All India Institute of Medical Sciences (AIIMS), New Delhi, graduating in 2016, and later achieved his D.M. in Clinical Haematology from the Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata in 2021. His strong academic trajectory reflects a blend of basic science foundation and clinical acumen, supported by an early inclination toward hematopathology, molecular diagnostics, and translational medicine.

Research Focus

Dr. Ghosh’s research lies at the intersection of clinical hematology, molecular pathology, and cellular therapies. His primary interests include outcome studies in acute leukemias, myelodysplastic syndromes (MDS), and chronic myeloid leukemia (CML), along with the optimization of transplant protocols and management of immunotherapy-related toxicities. He is actively involved in clinical trials and registry-based research, studying the efficacy and safety of novel agents like venetoclax, azacitidine, and HT-6184 in hematologic malignancies. Additionally, his work extends to exploring antimicrobial resistance patterns in transplant settings, the genetic characterization of thalassemia and hemoglobinopathies, and the real-world application of next-generation therapies such as CAR-T cells in Indian patient populations.

Experience

Dr. Ghosh’s professional journey reflects a steady progression through some of the most respected medical institutions in India and abroad. Since September 2023, he has been serving as a Consultant in Clinical Haematology and Cellular Therapies at Tata Medical Center, Kolkata. Previously, he completed a Leukemia and Bone Marrow Transplant Fellowship at Vancouver General Hospital, Canada (2022–2023), where he trained in advanced transplant methodologies and immunotherapeutic approaches. His earlier roles at Tata Medical Center included Clinical Associate and Senior Fellow, focusing on the management of transplant and immunotherapy patients. His training also encompasses a DM in Clinical Haematology (Medical College, Kolkata), MD Pathology (AIIMS, New Delhi), and extensive early experience as a Senior Resident in Haematology at NRSMCH, Kolkata. Collectively, these experiences have given him a deep clinical insight into hematological diseases, multidisciplinary care, and academic medicine.

Research Timeline & Activities

Dr. Ghosh’s research journey spans over a decade, beginning with molecular pathology and evolving toward translational clinical hematology. He currently serves as the Principal Investigator for the HCC registry study in Chronic Myeloid Leukemia (CML) initiated in 2024, and Co-Investigator for the MDS HT-6184-001 trial and PRIME trial on myeloid malignancies. He has contributed to numerous multicenter studies and presented his work at major international forums including SOHO (Houston, 2024), APBMT (Singapore, 2024), and Haematocon (New Delhi, 2019). His research timeline demonstrates a consistent focus on data-driven outcomes, quality improvement in transplant programs, and collaborative trials designed to enhance patient safety and treatment efficacy in hematologic cancers.

Awards & Honors

Dr. Ghosh’s excellence has been recognized with several prestigious honors. He received the Gold Medal for Best Outgoing Resident in Clinical Haematology (2020–2021) from the Medical College and Hospital, Kolkata, and the Dr. V. Ramalingaswami Medal (2016) from AIIMS, New Delhi, for his outstanding performance in pathology. During his academic career, he won multiple best oral and poster presentation awards at national conferences including APCON and Haematocon, along with numerous university distinctions in physiology, pathology, and forensic medicine. His awards highlight a consistent trajectory of academic distinction, clinical skill, and scientific innovation from undergraduate training through postdoctoral specialization.

Top Noted Publication

Among his wide-ranging publications in indexed international journals, Dr. Ghosh’s notable works include “Analysis of bloodstream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia” published in Annals of Hematology (2020), a study that remains influential in guiding infection control in hematology units. Another key contribution is “Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life” (Hemoglobin, 2024), which offers important real-world insights into treatment optimization in thalassemia. His publications collectively cover themes of stem cell transplantation, hematologic malignancies, molecular genetics, and supportive care, reflecting his comprehensive engagement with both clinical and laboratory research in modern hematology.

  • Paul SB, Das P, Mahanta M, Sreenivas V, Kedia S, Kalra N, Kaur H, Vijayvargiya M, Ghosh S, et al.
    Assessment of liver fibrosis in chronic hepatitis: comparison of shear wave elastography and transient elastography.
    Abdominal Radiology, 42(12), 2864–2873, 2017.
    Citations: 40
    Significance: Demonstrated comparative diagnostic accuracy of shear wave and transient elastography in assessing hepatic fibrosis, widely referenced in hepatology and imaging research.

  • Ghosh S, Chakraborty M, Samanta S, Sinha N, Saha S, Chattopadhyay A, Bhattacharyya M.
    Analysis of bloodstream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Annals of Hematology, 100(2), 395–403, 2021.
    Citations: 27
    Significance: Provided real-world insights into infection epidemiology and resistance trends in hematology patients, shaping antibiotic stewardship policies.

  • Kumar K, Dhull VS, Karunanithi S, Chakraborty PS, Roy SG, Ghosh S, Agarwala S, Tripathi M.
    Synchronous thoracic and abdominal enteric duplication cysts: accurate detection with (99m)Tc-pertechnetate scintigraphy.
    Indian Journal of Nuclear Medicine, 30(1), 59–61, 2015.
    Citations: 21
    Significance: Reported a rare dual enteric duplication case, highlighting the role of nuclear imaging in pediatric diagnostics.

  • Gupta B, Das P, Ghosh S, Manhas J, Sen S, Pal S, Sahni P, Upadhyay AD, Panda SK, Gupta SD.
    Identification of high-risk aberrant crypt foci and mucin-depleted foci in the human colon with study of colon cancer stem cell markers.
    Clinical Colorectal Cancer, 16(3), 204–213, 2017.
    Citations: 19
    Significance: Characterized early pre-neoplastic lesions and stem cell markers in colorectal cancer, contributing to early detection research.

  • Khanna G, Ghosh S, Barwad A, Yadav R, Das P.
    Mucosal Schwann cell hamartoma of gall bladder: a novel observation.
    Pathology, 50(4), 480–482, 2018.
    Citations: 13
    Significance: Described an unusual benign Schwann cell lesion of the gallbladder, expanding the pathological spectrum of biliary tract disorders.

Strengths for the Best Innovator Award

1. Pioneering Work in Stem Cell and Cellular Therapies

Dr. Ghosh has demonstrated outstanding innovation in developing and implementing advanced stem cell transplant protocols, including both autologous and allogeneic transplants for hematologic malignancies. His work has introduced refinements in transplant conditioning, GVHD management, and immune recovery, improving safety and success rates in complex clinical settings. His leadership in CAR-T cell therapy further underscores his commitment to bringing next-generation immunotherapies to the Indian healthcare landscape.

2. Translational Research Linking Laboratory and Clinical Medicine

With a strong foundation in pathology and hematology, Dr. Ghosh bridges molecular research and bedside practice. His studies on molecular characterization of hematologic and genetic disorders—including thalassemia, myeloid neoplasms, and pre-neoplastic colon lesions—have led to better diagnostic accuracy and therapeutic planning. His translational mindset ensures that laboratory discoveries are effectively transformed into meaningful clinical outcomes.

3. Leadership in Clinical Trials and Collaborative Research Networks

Dr. Ghosh plays a vital role in national and international clinical trials, serving as Principal Investigator for the HCC CML registry and Co-Investigator in global MDS and AML studies. His contributions to Haematology Care Consortium and ISBMT working groups reflect a deep commitment to collaborative science and large-scale data integration. These initiatives are helping shape policy and practice in hematologic oncology across India.

4. Innovation in Infection Management and Supportive Care

Through his highly cited research on bloodstream infections and antimicrobial resistance in hematology patients, Dr. Ghosh has pioneered infection-control strategies in immunocompromised populations. His work in developing evidence-based antibiotic policies and real-world data on resistant organisms has significantly improved outcomes in transplant and chemotherapy settings, marking a major advancement in supportive care innovation.

5. Academic Excellence and Knowledge Dissemination

Dr. Ghosh’s consistent academic distinction, multiple national awards, and participation in global conferences such as SOHO and APBMT highlight his leadership in knowledge creation and dissemination. His mentorship of trainees and his active role in clinical education foster a culture of inquiry, innovation, and excellence. His research outputs—spanning over twenty peer-reviewed papers—reflect both scientific rigor and the drive to translate evidence into impactful clinical practice.

Sumeesha Jaswal, Medicine, Best Researcher Award

Posted on by scizentox scizentoxLeave a Comment on Sumeesha Jaswal, Medicine, Best Researcher Award

Dr. Sumeesha Jaswal: Senior resident at Indira gandhi medical college, India

Dr. Sumeesha Jaswal is an accomplished psychiatrist with a focus on schizophrenia, psychosis, and psychiatric comorbidities. She completed her MD in Psychiatry with first position at Panjab University, Chandigarh, India. Her research encompasses immunological aspects of psychiatric disorders, effects of psychotropic medications on immune markers, and neuropsychiatric overlaps in systemic diseases. Currently a Senior Resident at Indira Gandhi Medical College, Shimla, she combines clinical expertise with active academic and research pursuits. She has presented nationally and internationally, contributing significantly to the fields of clinical psychiatry and neuroimmunology.

Online Profile

Google Scholar Profile

Dr. Sumeesha Jaswal’s research has garnered a total of 17 citations, with an h-index of 2 and an i10-index of 1. These metrics demonstrate the growing academic impact and recognition of her contributions in psychiatry and mental health research.

Education

  • MD Psychiatry (May 2019 – May 2022), Government Medical College and Hospital, Chandigarh, India
    Secured first position in Panjab University; thesis on “Effects of Clozapine on Immunoglobulins and Interleukin Levels and Its Clinical Correlation in Patients with Schizophrenia.”

  • MBBS (Aug 2013 – Dec 2018), Indira Gandhi Medical College and Hospital, Shimla, India
    Topped Himachal Pradesh University in first and second professional years; awarded distinction in Biochemistry and Forensic Medicine.
    Recipient of the “Sri Tribhuvan Nath Bhatnagar Memorial Grant.”
    Engaged in observership in Department of Clinical Psychology at Composite Regional Centre for Persons with Disabilities.

Research Focus

Dr. Jaswal’s research investigates the immunological mechanisms underlying schizophrenia, focusing on the role of clozapine and risperidone in modulating immunoglobulin and cytokine levels. She explores psychiatric comorbidities in dermatological conditions such as psoriasis, neuropsychiatric manifestations in systemic diseases like multiple sclerosis and scrub typhus, and the overlap between neurological and psychiatric presentations. Her work integrates clinical trials, observational studies, and psychometric assessment development.

Experience

  • Senior Resident, Department of Psychiatry
    Indira Gandhi Medical College and Hospital, Shimla (Nov 2022 – Present)
    Responsible for clinical care, teaching postgraduate students, and conducting research.

  • Senior Resident, Department of Psychiatry
    Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh (Jul 2022 – Oct 2022)
    Engaged in advanced psychiatric clinical services and academic training.

Research Timeline & Activities

  • July 2019 – May 2022: MD Psychiatry residency with thesis research on clozapine effects on immune markers in schizophrenia patients.

  • 2022 – Present: Active clinical research at IGMC Shimla, including studies on psychiatric comorbidities in psoriasis and neurological-psychiatric overlaps.

  • Regular presenter at national conferences including ANCIPS and IPS-NZ.

  • Reviewer and peer reviewer for international journals including International Journal of Research and Innovation in Social Science, BP International, and Mathews Journal of Psychiatry & Mental Health.

  • Participated in National Mental Health Survey Master Training at NIMHANS, Bengaluru (Nov 2024).

Awards & Honors

  • PB Buckshey Award for outstanding research on Clozapine’s immunological effects, IPS-NZ 2021.

  • GC Boral Award for research on neuropsychological predictors in OCD, IPS-NZ 2021.

  • First position in university during MBBS first and second years with distinctions.

  • Winner of All India Book Review Competition “Seeing the Suffering” by Indian Psychiatric Society.

  • Multiple poster and paper presentation awards at national and regional psychiatry conferences.

  • Awarded “Sri Tribhuvan Nath Bhatnagar Memorial Grant” during MBBS.

Top Noted Publication

Jaswal S, Thakur A, Lata S. Borderline Intellectual Functioning: A Masquerader in Patients with Confusing Psychopathology. Mathews Journal of Psychiatry and Mental Health, 2025;10(1):51.
This article highlights the clinical challenges in diagnosing borderline intellectual functioning amid complex psychiatric symptoms and emphasizes tailored approaches for accurate diagnosis and management.

  • COVID vaccination and mental health: An Indian perspective
    GP Singh, S Jaswal
    Published in Asian Journal of Psychiatry (2021)
    — Explores the intersection of COVID-19 vaccination and mental health issues in the Indian context.

  • Pattern of psychiatry referrals in a tertiary hospital teaching set-up
    S Jaswal, H Garg, A Kaur
    Published in Mathews Journal of Psychiatry & Mental Health (2023)
    — Examines referral patterns to psychiatry departments in a teaching hospital setting.

  • Development and psychometric testing of the Knowledge, Attitude, and Practice Questionnaire to assess knowledge, attitude, and practices regarding COVID-19 among patients
    N Chauhan, R Rohilla, D Aggarwal, S Jaswal, A Singh, P Arun
    Published in Industrial Psychiatry Journal (2022)
    — Focuses on creating and validating a questionnaire to evaluate public knowledge and behaviors related to COVID-19.

  • Borderline Intellectual Functioning: A Masquerader in Patients with Confusing Psychopathology
    S Jaswal, A Thakur, S Lata
    Published in Mathews Journal of Psychiatry & Mental Health (2025)
    — Discusses borderline intellectual functioning and its challenges in psychiatric diagnosis.

  • A fatal case of Anti-NMDAR encephalitis with fulminant psychosis
    S Jaswal, A Kumar
    Published in Industrial Psychiatry Journal (2025)
    — A case report describing a severe and fatal instance of anti-NMDAR encephalitis presenting with psychosis.

Strength suitable for a Best Researcher Award

1. Excellence in Academic Achievement and Research Quality

Dr. Jaswal has demonstrated exceptional academic performance, securing first positions during her MD Psychiatry and consistently excelling throughout her medical education. Her research output is marked by high scientific rigor and relevance, as evidenced by multiple peer-reviewed publications and increasing citation metrics. This reflects her commitment to producing meaningful and impactful psychiatric research that advances clinical understanding.

2. Innovative Research on Psychotropic Drug Immunomodulation

Her groundbreaking work exploring the immunological effects of antipsychotic medications, particularly clozapine, addresses critical gaps in understanding schizophrenia’s pathophysiology. By linking psychotropic drug action to immune modulation, Dr. Jaswal has opened new pathways for research and treatment, potentially improving patient outcomes through precision medicine.

3. Strong Clinical-Research Integration

Dr. Jaswal exemplifies the ideal clinician-researcher by integrating her frontline clinical experiences with scientific inquiry. Her research is deeply informed by patient care challenges, which enhances the practical applicability of her findings. This synergy ensures that her work contributes directly to improving diagnostic accuracy, treatment protocols, and holistic patient management.

4. Consistent Contribution to Scholarly Community

Beyond her own research, Dr. Jaswal actively contributes to the broader academic community through peer reviewing for international journals, mentoring students, and regularly presenting her work at national and international psychiatry conferences. This engagement promotes scholarly discourse, knowledge exchange, and the nurturing of future researchers in the field.

5. Recognition through Prestigious Awards and Grants

Dr. Jaswal’s research excellence has been acknowledged through several prestigious awards, such as the PB Buckshey Award for outstanding research on clozapine’s immunological effects and the GC Boral Award for contributions to neuropsychological research. Additionally, competitive grants like the Sri Tribhuvan Nath Bhatnagar Memorial Grant highlight her ability to secure funding, supporting her ongoing innovative research projects.

Jayanthi Lingaraj, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Jayanthi Lingaraj, Medicine, Best Innovator Award

Dr. Jayanthi Lingaraj: Assistant Professor at Meenakshi Academy for Higher education and Research, India

Dr. Jayanthi Lingaraj is a distinguished Oral and Maxillofacial Surgeon with over three years of clinical experience, excelling in maxillofacial trauma, orthognathic surgery, and facial aesthetics. She is a Gold Medalist in her Master of Dental Surgery program and holds a prestigious fellowship in Cleft Lip, Palate, and Craniofacial Surgery from Cleft Children International, Switzerland. Her professional mission is to deliver compassionate, evidence-based care while advancing surgical techniques in craniofacial reconstruction and aesthetic dentistry.

Online Profiles

Scopus Profile

Dr. Jayanthi Lingaraj is affiliated with Meenakshi Cleft and Craniofacial Centre in Chennai, India. She has an established academic presence with a Scopus Author ID: 55451066100, under which she has published 12 documents that have been cited 141 times, reflecting an h-index of 8. Dr. Jayanthi is connected to ORCID for enhanced research visibility and digital identity management, allowing seamless integration and verification of her scholarly work across platforms.

Education

Dr. Jayanthi completed her MDS in Oral and Maxillofacial Surgery at Meenakshi Ammal Dental College, Chennai, where she graduated with top honors as a Gold Medalist. Her foundational dental education was obtained from Sathyabama Dental College, where she earned her BDS degree with first-class distinction. Further, she specialized in cleft and craniofacial surgery through a rigorous fellowship with Cleft Children International in Switzerland. Complementing her surgical expertise, she has pursued advanced certification courses in facial aesthetics, hair transplantation, and aesthetic rhinoplasty, ensuring a comprehensive skill set.

Research Focus

Her research portfolio centers on improving surgical outcomes in cleft lip and palate repair, craniofacial deformity correction, and post-surgical healing processes. She is particularly focused on regenerative medicine applications, such as combining bone marrow mononuclear cells with platelet-rich plasma for alveolar cleft bone regeneration. Additionally, she investigates neuro-sensory disturbances following third molar extraction and evaluates the efficacy of botulinum toxin in scar management, aiming to enhance both functional recovery and aesthetic results.

Experience

Currently serving as an Assistant Professor at the Department of Oral and Maxillofacial Surgery, Meenakshi Ammal Dental College, Dr. Jayanthi also fulfills her role as a Surgical Fellow at Cleft Children International based in Chennai. She has provided expert consultation across numerous dental and multi-specialty clinics in the region, offering advanced surgical care. With extensive teaching experience, she has delivered multiple undergraduate lectures and actively mentors students in clinical and research settings, fostering the next generation of oral surgeons.

Research Timeline & Activities

Dr. Jayanthi’s research contributions began with material sciences in restorative dentistry and expanded into surgical innovations and clinical studies. From 2017 onwards, she has published in high-impact journals, focusing on areas such as tissue thickness in implant placement and congenital craniofacial conditions. Current projects include evaluating placental extract in third molar socket healing, novel bone regeneration techniques for alveolar clefts, and randomized control trials on botulinum toxin use in cleft scar management. She consistently engages in guiding students through research methodologies and publication processes.

Awards & Honors

Throughout her academic and professional journey, Dr. Jayanthi has garnered numerous accolades recognizing her scholarly excellence and clinical skills. Highlights include double Gold Medals for academic achievement at MAHER University, a Post Graduate Academic Excellence Award, and several awards for best papers and posters at national and state dental conventions. These honors underscore her dedication to clinical innovation, research quality, and educational leadership.

Top Noted Publication

Dr. Jayanthi Lingaraj’s notable publication, titled “Oral Vitamin B12 Versus Intra-Nasal Vitamin B12 in Transient Neurosensory Disturbances Following Third Molar Surgery: A Prospective Cohort Study,” is set to be published in the Journal of Maxillofacial and Oral Surgery in 2025. This study evaluates the comparative efficacy of oral and intranasal Vitamin B12 in managing temporary nerve disturbances post-third molar extraction, offering important clinical insights for improving patient outcomes in oral surgery.

Strengths for the Best Innovator Award

  1. Pioneering Research in Regenerative Medicine
    Dr. Jayanthi is at the forefront of integrating novel regenerative techniques, such as the use of bone marrow mononuclear cells combined with platelet-rich plasma for alveolar cleft bone regeneration. This innovative approach has the potential to revolutionize cleft repair surgeries, significantly improving healing outcomes and patient quality of life.

  2. Clinical Innovation in Neurosensory Recovery
    Her research on comparing oral versus intranasal Vitamin B12 for managing transient neurosensory disturbances following third molar surgery reflects a unique clinical innovation that could transform postoperative care protocols and enhance nerve recovery for patients undergoing oral surgeries.

  3. Multidisciplinary Surgical Expertise
    Dr. Jayanthi combines advanced surgical skills in maxillofacial trauma, orthognathic surgery, cleft, craniofacial reconstruction, and facial aesthetics. This multidisciplinary mastery allows her to innovate by merging functional and aesthetic surgical techniques for holistic patient care.

  4. Commitment to Evidence-Based Practice and Education
    By actively mentoring students and guiding research, Dr. Jayanthi fosters a culture of scientific inquiry and innovation. Her leadership in academic and clinical settings promotes the translation of cutting-edge research into practical surgical applications.

  5. Recognition Through High-Impact Publications and Awards
    Her consistent track record of publishing in reputed journals, coupled with prestigious accolades like multiple Gold Medals and best paper/poster awards, highlights her innovative contributions and the high regard in which her work is held by the professional community.

Prasant Chandra, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Prasant Chandra, Medicine, Best Innovator Award

Dr. Prasant Chandra: Consultant at Aditya Birla Memorial Hospital, India

Dr. Prasant Chandra is an accomplished Surgical Oncologist with over 15 years of clinical and academic experience. Specializing in minimally invasive and robotic surgery, he combines advanced surgical techniques with a patient-centered approach. Currently, he practices at Aditya Birla Memorial Hospital in Pune and is recognized for his innovative contributions to cancer treatment and surgical oncology education.

Online Profiles

ORCID Profile

Education

Dr. Chandra’s foundational medical education began with an M.B.B.S degree from BJ Medical College, Pune, completed in 2010. Following this, he completed a rigorous internship at BJ Medical College and Sassoon General Hospital. He earned his D.N.B in General Surgery at Poona Hospital & Research Centre and further specialized by achieving a Dr.N.B in Surgical Oncology from Ruby Hall Clinic. He has enhanced his expertise with certifications and fellowships in minimal access and robotic surgery from prestigious institutes, including the World Laparoscopy Hospital.

Research Focus

Dr. Chandra’s research primarily centers on improving outcomes in surgical oncology through innovations in minimally invasive and robotic techniques. He investigates predictive models for cancer prognosis, developing scoring systems such as the Oncoscore app, which aids in assessing survival chances for tongue cancer patients and predicting surgical margin risks in rectal cancer. His work also includes rare case studies and advancements in laparoscopic hernia repair.

Experience

With extensive clinical exposure, Dr. Chandra has held senior surgical oncology roles at top hospitals including Inlaks & Budhrani, Ruby Hall Clinic, and DY Patil Medical College. His consultancy roles at Oncolife Cancer Care Centre and currently at Aditya Birla Memorial Hospital highlight his leadership in cancer care. He has comprehensive experience operating da Vinci Si and Xi robotic surgical systems, demonstrating proficiency in cutting-edge surgical technologies.

Research Timeline & Activities

Dr. Chandra has maintained a steady output of scholarly articles and clinical studies from 2016 through 2025, contributing to key oncology journals. His research spans clinical trials, retrospective studies, and case reports addressing diverse oncological challenges. He actively participates in academic conferences and collaborates with multidisciplinary teams to advance surgical oncology knowledge.

Awards & Honors

Dr. Chandra’s dedication has been recognized through several prestigious awards, including the Young Researcher Award from DY Patil University and a 3rd prize for best paper presentation at the Indian Cancer Congress 2023. He is also the author of “Chandra’s Concise Textbook of Surgical Oncology,” the first comprehensive Indian textbook in the field, marking a significant milestone in surgical oncology literature.

Top Noted Publication

Among his numerous publications, the study titled “Comparison of the Clinical Outcome and Complications in Laparoscopic Hernia Repair of Inguinal Hernia With Mesh Fixation Using Fibrin Glue vs Tacker” published in the Indian Journal of Surgery (2016) stands out. This research has influenced surgical practices by evaluating mesh fixation techniques, improving patient outcomes in hernia repair surgery.

  • Double Troubles – Managing a Series of Cases with Dual Primary Malignancies
    Medical Journal of Dr. D.Y. Patil Vidyapeeth (March 2025)
    DOI: 10.4103/mjdrdypu.mjdrdypu_531_24
    Contributors: Santhosh Nanjappa, Saurabh Boralkar, Prasant Chandra, Samir Gupta, Mangesh Londe

  • Margin Shrinkage in Oral Squamous Cell Carcinoma: A Prospective Observational Study
    Indian Journal of Otolaryngology and Head & Neck Surgery (March 2025)
    DOI: 10.1007/s12070-025-05375-x
    Contributors: Advait A. Vaidya, Samir Gupta, Archana Chirag Buch, Prasant Chandra, Tejus V. Nagireddy

  • Development of Margin Compromise Ordinal Score (MCOS) Based on Analysis of Various Factors Associated with Margin Compromise in Patients of Carcinoma Rectum Undergoing Restorative Surgery
    Indian Journal of Surgical Oncology (March 2025)
    DOI: 10.1007/s13193-025-02244-5
    Contributors: Prasant Chandra, Samir Gupta, Sujai Hegde, Sanjay Deshmukh, Tejus Nagireddy, Ajita Pralhad Kendre

  • Novel Scoring Formula to Predict Survival in Patients of Primary Tongue Cancer Belonging to Tobacco Chewing Population
    Indian Journal of Surgical Oncology (December 2023)
    DOI: 10.1007/s13193-023-01799-5
    Contributors: Prasant Chandra, Sanjay P. Deshmukh, Ajita Kendre, Moulik Gupta

  • Primary Spinal Glioblastoma Multiforme Involving Conus Medullaris – A Rare Case Report
    International Journal of Creative Research Thoughts (September 2022)
    DOI: http://doi.one/10.1729/Journal.31546
    Contributor: Prasant Chandra

Strengths for the Best Innovator Award

  1. Pioneering Development of Predictive Scoring Systems
    Dr. Chandra developed innovative scoring tools such as the Oncoscore app and the Margin Compromise Ordinal Score (MCOS), which aid clinicians in accurately predicting survival outcomes and surgical risks for complex cancer cases. These tools represent a significant advancement in personalized oncology care.

  2. Expertise in Cutting-Edge Minimally Invasive and Robotic Surgery
    He has mastered the use of da Vinci Si and Xi robotic surgical systems, applying advanced robotic techniques to improve surgical precision, reduce patient recovery time, and enhance overall treatment outcomes, demonstrating leadership in surgical innovation.

  3. Author of India’s First Comprehensive Surgical Oncology Textbook
    By authoring Chandra’s Concise Textbook of Surgical Oncology, Dr. Chandra has filled a crucial gap in Indian medical education, providing a valuable resource that integrates modern surgical oncology principles with clinical practice, boosting knowledge dissemination nationwide.

  4. Innovative Clinical Research with Real-World Impact
    His research not only advances theoretical knowledge but also directly influences clinical practice, evidenced by impactful studies on laparoscopic hernia repair techniques and management of dual primary malignancies, which have practical applications in improving patient care protocols.

  5. Multidisciplinary Collaboration and Leadership
    Dr. Chandra actively collaborates across specialties and institutions, fostering innovation through team-based research and clinical trials. His role as a consultant and educator ensures the integration of new surgical technologies and evidence-based practices into routine cancer care.

Sunisha Arora, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Sunisha Arora, Medicine, Best Innovator Award

Dr. Sunisha Arora: Consultant at Fortis memorial research institute, India

Dr. Sunisha Arora is a dedicated Pediatric Hematologist & Oncologist with specialized expertise in Bone Marrow Transplantation, Pediatric Oncology, and General Pediatrics. She brings a compassionate approach to managing complex hematological malignancies and critical pediatric cases. Based in Gurugram, India, Dr. Arora combines clinical excellence with active research and teaching roles. She is recognized for her strong commitment to improving pediatric cancer care and outcomes.

Online Profiles

Scopus Profile

Dr. Sunisha Arora is affiliated with Medanta – The Medicity, Gurugram, India, and holds a Scopus ID: 57225205301. Her research contributions include 13 published documents cited 25 times across 24 different works, reflecting a growing influence in pediatric hematology and oncology. She has an h-index of 3, indicating her work’s recognition and impact within the academic community. Dr. Arora is encouraged to connect her research profile with ORCID to further enhance visibility and collaboration opportunities.

Education

She earned her Fellowship of National Board (FNB) in Pediatric Hematology & Oncology from Medanta, The Medicity, Gurugram (2021–2023), where she gained specialized training in bone marrow transplantation and pediatric cancer care. She completed her MD Pediatrics at GSVM Medical College, Kanpur (2015–2018), and her MBBS from MVJ Medical College & Research Hospital, Bangalore (2008–2013). Dr. Arora’s academic foundation was built on consistently high performance during school years at Kendriya Vidyalayas in Bangalore and Assam.

Research Focus

Dr. Arora’s research interests include pediatric infections in oncology patients, management of COVID-19 in immunocompromised children, graft-versus-host disease (GVHD), and outcomes of stem cell transplantation in children. She is committed to advancing knowledge on complications following transplantation and improving patient survival and quality of life through evidence-based interventions.

Experience

Currently, Dr. Arora works as an Associate Consultant in Hematology & Bone Marrow Transplantation at Fortis Memorial Research Institute, Gurugram. She has previously held similar consultant roles at Max Super Specialty Hospital, Patparganj, and was a Senior Resident and Fellow in Pediatric Hematology/Oncology and BMT at Medanta. Her clinical experience spans across critical care, general pediatrics, and specialized pediatric oncology services, managing both routine and complex cases.

Research Timeline & Activities

Dr. Arora initiated her research career with a prospective study on Central Venous Pressure measurement in sick neonates (2015–2017), contributing valuable clinical data for neonatal management. Over the years, she has conducted outcome audits on acute lymphoblastic leukemia (ALL), neuroblastoma, and hematopoietic stem cell transplantation (HSCT)-related graft-versus-host disease. Her active participation in international and national conferences underscores her commitment to ongoing professional development and knowledge dissemination.

Awards & Honors

Dr. Arora’s work has been recognized with multiple awards, including 1st Prize at UP Pedicon 2016 for her study on Vitamin D supplementation and Best Poster Presentation at PHOCON Jammu. She has also received commendations for her oral and poster presentations at conferences such as SIOP, EBMT, and PHO Conferences, reflecting her strong research and clinical contributions.

Top Noted Publication

One of Dr. Arora’s notable publications is featured in the Pediatric Hematology Oncology Journal, focusing on graft-versus-host disease management and transplantation outcomes in pediatric patients. This publication has contributed important insights into improving post-transplant care protocols and minimizing complications, benefiting clinicians and researchers in pediatric hematology-oncology worldwide.

One of Dr. Sunisha Arora’s recent significant publications is an open-access article titled “Treatment of Pediatric Acute Lymphoblastic Leukemia in India as per modified BFM 95 protocol with Minimal Residual Disease monitoring,” published in Hematology (United Kingdom) in 2025. This study addresses tailored treatment approaches for pediatric acute lymphoblastic leukemia (ALL) in the Indian context, emphasizing the role of Minimal Residual Disease (MRD) monitoring to improve treatment outcomes.

Strengths for Best Innovator Award

  1. Innovative Pediatric Oncology Treatment Protocols
    Dr. Arora has contributed to the adaptation and implementation of the modified BFM 95 protocol with Minimal Residual Disease (MRD) monitoring for pediatric acute lymphoblastic leukemia in India. This innovation in treatment tailoring enhances precision and improves outcomes for children in resource-constrained settings.

  2. Pioneering Research in Stem Cell Transplantation & GVHD
    Her focused research on graft-versus-host disease (GVHD) management and transplantation outcomes has led to improved post-transplant care protocols. These innovations help minimize complications and enhance survival rates in pediatric hematology-oncology patients.

  3. Integration of Research with Clinical Practice
    Dr. Arora effectively bridges clinical expertise with active research, applying evidence-based interventions in real-world settings. Her prospective studies and outcome audits directly inform and improve patient care strategies, exemplifying translational innovation.

  4. Leadership in Multidisciplinary Pediatric Care
    Her roles across top institutes and multidisciplinary teams, including critical care and bone marrow transplantation, demonstrate innovative leadership in complex pediatric cases, ensuring comprehensive and personalized care approaches.

  5. Active Knowledge Dissemination & Capacity Building
    Through frequent presentations at national and international conferences and engagement in workshops, Dr. Arora actively promotes knowledge sharing and professional development in pediatric hematology-oncology, fostering innovation in the wider medical community.

Ankit Kumar, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Ankit Kumar, Medicine, Best Innovator Award

Dr. Ankit Kumar: Associate Professor at School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi GT Road, Phagwara, Punjab, India

Dr. Ankit Kumar Yadav is a seasoned academician and researcher currently serving as an Associate Professor at the School of Pharmaceutical Sciences, Lovely Professional University (LPU), Punjab, India. With over 12 years of combined experience in teaching, research, and industry, he specializes in pharmaceutics, drug delivery systems, pharmaceutical regulatory affairs, and pharmacovigilance. He has been instrumental in mentoring students across various academic levels and contributing to institutional growth through entrepreneurship and intellectual property development. His academic vision is rooted in integrating innovation with education, and his professional journey reflects a consistent commitment to research excellence, curriculum innovation, and practical application of pharmaceutical sciences in healthcare and industrial settings.

Online Profiles

Scopus Profile

Dr. Ankit Kumar Yadav is a pharmaceutical sciences researcher with 892 citations from 676 documents and an h-index of 19 according to Scopus. His research output includes 46 peer-reviewed documents focusing on pharmaceutics, targeted drug delivery, and pharmaceutical regulatory sciences. He actively contributes to advancements in nanoformulations, drug delivery technologies, and pharmacovigilance systems, with a strong emphasis on translational research and intellectual property development.

Education

Dr. Yadav holds a Ph.D. in Pharmaceutical Sciences from Lovely Professional University, Phagwara, Punjab (2020), where he completed his doctoral research on the formulation and evaluation of colon-targeted mini tablets of 5-Fluorouracil. He earned his M.Pharm with a specialization in Quality Assurance from the same university in 2013, with a thesis focused on novel diffusion cell systems for skin permeation studies. His academic journey began with a Bachelor’s in Pharmacy (B.Pharm) from Dr. B.R. Ambedkar University, Agra, completed in 2009. This strong foundation in both theoretical knowledge and applied pharmaceutical sciences has enabled him to develop deep expertise in formulation design, analytical method development, and regulatory compliance.

Research Focus

Dr. Yadav’s research interests lie at the intersection of targeted drug delivery, nano-formulations, phytopharmaceuticals, and regulatory science. His work primarily focuses on nanoemulgel, SNEDDS, and colon-targeted drug delivery systems, aiming to improve drug bioavailability and therapeutic efficacy while minimizing systemic side effects. Additionally, his interest in AI-driven pharmacovigilance systems, biosensors, and real-time disease monitoring tools reflects a multidisciplinary approach that blends pharmaceutical technology with emerging healthcare innovations. His portfolio includes several innovative formulations combining modern and traditional medicines for chronic diseases such as diabetes, arthritis, and cancer, with a strong emphasis on translational and patentable research.

Experience

With a rich blend of academic and industrial experience spanning over 12 years, Dr. Yadav has significantly contributed to the education and pharmaceutical sectors. He is currently working as an Associate Professor at Lovely Professional University since April 2022, where he also serves as a Copyright Cell Coordinator, entrepreneurship coach, and project mentor. Previously, he worked as an Associate Professor at Amity University Madhya Pradesh and as an Assistant Professor at LPU. His industry stint includes working as a Senior Associate Medical Writer in pharmacovigilance at PharmaVigilance Ltd., where he gained hands-on experience in drug safety documentation. His teaching experience covers both undergraduate and postgraduate levels, and he has handled a wide range of subjects from pharmaceutics and biotechnology to regulatory affairs and product development.

Research Timeline & Activities

Dr. Yadav has maintained an active and progressive research timeline, beginning with his doctoral work in 2013, followed by continuous involvement in academic mentorship, formulation development, patent filing, and scholarly publishing. To date, he has filed 13 patents (with 2 granted and 10 more in the pipeline), authored 43 publications, and received 39 copyrights. He regularly guides Ph.D., M.Pharm, and B.Pharm students on interdisciplinary projects involving herbal formulations, nano-delivery systems, analytical method validation, and AI-based health systems. He has led hands-on workshops on HPLC, UV-Vis spectroscopy, tablet compression, and dissolution testing, and he plays a key role in research-driven entrepreneurship within LPU, including product development and sales of herbal products like chyawanprash, chocolates, and first-aid kits.

Awards & Honors

Dr. Yadav’s academic excellence and research contributions have been recognized through multiple honors and institutional awards. He was placed on the University Honor Roll by Lovely Professional University for achieving 94.95% in Ph.D. coursework and received the Research Appreciation Award in 2018 for his contributions to pharmaceutical research. His work in patentable innovations and student mentorship has also earned appreciation from faculty bodies and research councils. In addition to academic recognition, he has been commended for successfully coordinating entrepreneurship initiatives and for fulfilling institutional goals in admissions, placements, and intellectual property management.

Top Noted Publication

One of Dr. Yadav’s most impactful publications is “Catering the Need of Drug Manufacturing Standard in India: An Update to Indian Pharmacopoeia”, published in Therapeutic Innovation & Regulatory Science (2025), which addresses critical regulatory gaps and standardization processes in Indian pharmaceutical manufacturing. Another notable work is the article “A Possible Approach to Overcome the Systemic Toxicity of Azathioprine through Nanoemulgel”, published in EXCLI Journal (2025), showcasing a novel drug delivery strategy to enhance therapeutic safety. His work on xanthohumol-loaded lipid carriers for Alzheimer’s disease and Ayurvedic formulations for arthritis has received significant attention in both academic and clinical research communities, emphasizing his interdisciplinary approach and commitment to public health innovation.

  1. Pharmaceutical Standardization and Comparative Study of Varunadi Kvatha Churna as Varunadi Ghana Vati/Tablet and Varunadi Pravahi Kvatha
    Published in Journal of Natural Remedies (2024), this study provides a detailed standardization and comparative analysis of traditional Ayurvedic formulations, contributing to the scientific validation of herbal medicines.

  2. Erratum to – Chitosan Modified 5-Fluorouracil Nanostructured Lipid Carriers for Treatment of Diabetic Retinopathy in Rats: A New Dimension to an Anticancer Drug
    Published in International Journal of Biological Macromolecules (2023), this research explores innovative nanostructured lipid carriers for targeted drug delivery of 5-fluorouracil, enhancing treatment efficacy for diabetic retinopathy.

  3. Unravelling the Impact of Human Papillomavirus (HPV): A Comprehensive Exploration of its Role in Cancer Progression and Global Health Challenges
    A conference paper that investigates the epidemiology and pathogenesis of HPV, emphasizing its critical role in cancer development and the global health burden.

  4. Phonophoresis in Physiotherapy: Mechanisms, Applications, and Emerging Trends for Enhanced Drug Delivery and Therapeutic Efficacy
    This open-access conference paper reviews phonophoresis technology, detailing its mechanism and emerging applications in drug delivery for musculoskeletal pain management.

Strength for the Best Innovator Award

1. Pioneering Targeted Drug Delivery Systems

Dr. Yadav has developed advanced nano-formulations such as nanoemulgels, SNEDDS, and colon-targeted mini tablets that significantly enhance drug bioavailability and reduce systemic toxicity. His work on targeted delivery, especially with anticancer and chronic disease drugs, reflects cutting-edge innovation in pharmaceutical technology.

2. Integration of Traditional and Modern Medicine

He bridges Ayurvedic formulations with contemporary pharmaceutical techniques, exemplified by his standardization and comparative studies of herbal medicines like Varunadi Kvatha Churna. This multidisciplinary approach promotes evidence-based validation and modernization of traditional healthcare.

3. Intellectual Property Leadership and Patent Development

With over 13 patent filings (including granted patents) and 39 copyrights, Dr. Yadav has demonstrated strong innovation output and commercialization potential. His proactive approach in translating research into protected, market-ready technologies highlights his entrepreneurial mindset.

4. AI-Driven Pharmacovigilance and Healthcare Innovations

Dr. Yadav’s work extends beyond formulations to incorporate AI tools for pharmacovigilance and real-time disease monitoring systems, showcasing innovation at the intersection of pharmaceuticals and digital health. This forward-thinking integration aims to improve patient safety and healthcare delivery.

5. Mentorship and Research-Driven Entrepreneurship

As a mentor and entrepreneurship coach, Dr. Yadav fosters innovation by guiding students and startups in product development, patent filing, and commercialization, including herbal products like chyawanprash and first-aid kits. His leadership cultivates an ecosystem of innovation within academia and industry.

Fumei Shang, Medicine, Innovative Researcher Award

Posted on by scizentox scizentoxLeave a Comment on Fumei Shang, Medicine, Innovative Researcher Award

Dr. Fumei Shang: Attending physician at Nanyang City Central Hospital, China

Dr. Fumei Shang is an accomplished attending physician and oncology researcher from China, specializing in tumor biology and the interplay between microbial flora and cancer. Holding a PhD in Oncology, she combines clinical expertise with advanced scientific research, particularly focusing on how intestinal microbiota affects tumor progression and immunotherapy outcomes. Known for her dedication, strong sense of responsibility, and excellent communication skills, Dr. Shang has contributed significantly to both clinical practice and academic research.

Online Profiles

Scopus Profile

Dr. Fumei Shang is currently affiliated with the Cancer Center in San Diego, United States, and has a strong international academic presence. Her Scopus Author ID is 56808889300, with a record of 13 published documents, 314 citations across 311 documents, and an h-index of 7, reflecting the growing impact and relevance of her research. She is encouraged to link her Scopus profile to ORCID for broader academic visibility and integration. Dr. Shang actively reviews for peer-reviewed journals and is recognized in the global oncology and microbiome research communities.

Education

Dr. Shang completed her doctoral studies in Oncology, where she extensively studied tumor microenvironment dynamics and the role of microbial communities in cancer biology. Her education provided a solid foundation in clinical oncology, molecular biology, and bioinformatics, equipping her with skills to integrate multi-omics approaches and machine learning techniques in cancer research.

Research Focus

Her primary research explores the complex interactions between tumors and microbial flora, with an emphasis on intestinal bacteria’s influence on immune response and immunotherapy efficacy in cancers such as non-small cell lung cancer and colorectal cancer. She also investigates microbial biomarkers predictive of therapeutic outcomes and the potential of microbiota transplantation as an adjuvant cancer treatment.

Experience

Dr. Shang has an extensive track record as principal investigator and collaborator on numerous research projects funded by national and provincial grants, including six projects where she served as the lead applicant. She has published 12 peer-reviewed articles, with several focusing on the tumor microbiome and immunotherapy. She is also an active peer reviewer for several respected scientific journals, contributing her expertise to advancing oncology research globally.

Research Timeline & Activities

Since 2015, Dr. Shang has led and contributed to a variety of research initiatives, ranging from undergraduate student training projects to major provincial scientific research programs. Her recent projects include studies on the modulation of immunotherapy efficacy through intestinal flora and the development of predictive models for treatment response in gene-negative NSCLC patients. These activities underscore her continuous commitment to bridging clinical oncology and microbiome science.

Awards & Honors

Dr. Shang’s research has earned significant recognition, particularly her highly cited review on Fusobacterium nucleatum and colorectal cancer, which has been acknowledged by leading journals such as Nature Reviews Gastroenterology & Hepatology. She is an active member of multiple professional oncology associations in China, including committees dedicated to tumor diagnosis, cancer prevention, and lung cancer research, reflecting her leadership and influence in the field.

Top Noted Publication

Her landmark paper, “Fusobacterium nucleatum and colorectal cancer: A review,” published in World Journal of Gastrointestinal Oncology (2018), has been cited over 100 times and is considered a seminal work in the understanding of microbial contributions to colorectal carcinogenesis. This publication has influenced further research on the tumor microbiome and been highly praised in reviews by top-tier journals, highlighting Dr. Shang’s role as a thought leader in this area.

1. Shang, F., Huang, M., Ji, Y., Zhang, S., et al.
Harnessing Machine Learning and Multiomics to Construct a Tumor-Specific T Cell Signature for Prognostic Assessment and Precision Medicine in Lung Adenocarcinoma
Annals of Surgical Oncology, Sep 2025
This study integrated scRNA-seq, bulk transcriptomic data, and spatial transcriptomics to construct a T cell-related gene prognostic indicator (TRGPI) for lung adenocarcinoma (LUAD). The model demonstrated strong predictive value for immunotherapy response and survival, with TPI1 identified as a key TRG. This work presents a significant advancement in precision oncology and immunotherapy stratification.

**2. Jin, M., Fan, Q., Shang, F., et al.
Fusobacteria Alterations Are Associated With Colorectal Cancer Liver Metastasis and a Poor Prognosis
Oncology Letters, Mar 2024
This study used 16S rRNA sequencing across multiple cohorts to show that Fusobacteria enrichment is consistently associated with colorectal cancer liver metastasis (LM) and poor survival outcomes. It identified Fusobacteria as a potential microbial biomarker for metastasis and prognosis, contributing to microbiota-based diagnostics in CRC.

**3. Cao, Y., Shang, F., Jin, M., et al.
Changes in Bacteroides and the Microbiota in Patients With Obstructed Colorectal Cancer: A Retrospective Cohort Study
BJS Open, Nov 2023
This retrospective analysis revealed that CRC patients with intestinal obstruction exhibit significantly altered microbial diversity, particularly an increase in Bacteroides. Obstruction was associated with worse clinical outcomes and shifts in tumor microecology, indicating a role of the microbiota in modulating CRC progression.

**4. Shang, F., Cao, Y., Wan, L., et al.
Comparison of Helicobacter pylori Positive and Negative Gastric Cancer via Multi-Omics Analysis
mBio®, Oct 2023
This multi-omics investigation uncovered significant genetic, microbial, and metabolic differences in gastric cancer patients with and without H. pylori infection. It identified novel biomarkers (e.g., GCG, APOA1, IGFBP1) and 295 differential metabolites, providing mechanistic insight into H. pylori-associated carcinogenesis.

**5. Jiang, Z., Yan, L., Deng, S., Shang, F., et al.
Development and Interpretation of a Clinicopathological-Based Model for the Identification of Microsatellite Instability in Colorectal Cancer
Disease Markers, Feb 2023
This study utilized machine learning (RF, SVM, XGBoost) to build predictive models for identifying dMMR/pMMR status using clinical features. The random forest model outperformed traditional logistic regression, offering a fast, cost-effective alternative to molecular testing in CRC treatment planning.

Strength for the Innovative Researcher Award:

1. Pioneering Research at the Tumor-Microbiome Interface

Dr. Shang has made groundbreaking contributions to the understanding of how microbial flora influences cancer progression and treatment, especially in colorectal and lung cancers. Her highly cited review on Fusobacterium nucleatum and colorectal cancer has shaped current perspectives in the field and established microbial biomarkers as viable clinical tools. Her research continues to bridge gaps between oncology and microbiome science, a frontier area in precision medicine.

2. Integration of Multi-Omics and Machine Learning in Oncology

In her recent work published in Annals of Surgical Oncology (2025), Dr. Shang demonstrated exceptional innovation by integrating single-cell RNA sequencing, spatial transcriptomics, and bulk RNA data to construct a T cell prognostic signature (TRGPI) for lung adenocarcinoma. This project reflects her strength in data-driven precision oncology, combining bioinformatics, immunology, and AI for clinically translatable outcomes.

3. International Recognition and Collaborative Impact

With over 314 citations and an h-index of 7, Dr. Shang’s research has garnered international attention. Her transition from China’s Nanyang City Central Hospital to the Cancer Center in San Diego has facilitated impactful cross-border collaborations, enhancing the global relevance of her work. Her dual affiliation exemplifies her role as a global academic connector and research leader.

4. Clinical Translation and Diagnostic Innovation

Dr. Shang has consistently aligned her research with clinical applicability. For example, her clinicopathological model for MSI prediction in CRC (published in Disease Markers, 2023) offers a low-cost, high-accuracy alternative to molecular testing, demonstrating her ability to translate computational models into real-world diagnostics that benefit patients in resource-limited settings.

5. Leadership in Funded Research and Mentorship

Dr. Shang has led six nationally and provincially funded research projects, underlining her ability to design, secure, and lead innovative investigations. Her mentorship of undergraduate research projects and collaboration in multidisciplinary studies reflect her dedication to capacity-building and scientific leadership, nurturing the next generation of oncology researchers.

Lin Shen, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Lin Shen, Medicine, Best Innovator Award

Dr. Lin Shen: Associate Research Fellow & Postdoctoral Researcher, Wenzhou Medical University, China

Title/Designation: Dr
Name: Lin Shen
Current Role/Designation: Associate Research Fellow & Postdoctoral Researcher, Wenzhou Medical University
Organization/Institution Details: Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China
Country: China
Subject Track: Medicine
Key Areas of Expertise: Immunometabolism and its regulatory roles in multiple disease models
Award Category: Best Innovator Award

Dr. Lin Shen is an accomplished postdoctoral researcher specializing in immunometabolism and its critical regulatory roles across multiple disease models, particularly atherosclerosis and cancer. With a robust background in surgery and molecular medicine, Dr. Shen’s work bridges fundamental biological mechanisms and translational applications. Currently, Dr. Shen holds dual postdoctoral appointments at the National University of Singapore and Wenzhou Medical University, contributing to cutting-edge research on nano-drug delivery platforms and metabolic reprogramming of immune cells to combat chronic inflammatory diseases. In addition to research, Dr. Shen serves in leadership roles within clinical departments, fostering integration between research and patient care.

Online Profiles

ORCID Profile

Scopus Profile

Dr. Lin Shen is affiliated with Lishui Central Hospital, Lishui, China, and has established a strong scholarly presence with 36 publications cited by over 470 documents. With a notable h-index of 14, Dr. Shen’s research contributions have gained substantial recognition within the scientific community. His work is indexed in major databases including Scopus (Author ID: 57224404551) and ORCID, facilitating broad accessibility and citation tracking.

Education

Dr. Shen completed a Ph.D. in Surgery from Wenzhou Medical University in 2023, under the mentorship of Professor Jiansong Ji, focusing on molecular and cellular mechanisms in disease pathology. Prior to that, he earned a Master’s degree in Surgery from Shandong First Medical University in 2020, where his research was guided by Professor Bin Ning. His foundational training began with a Bachelor of Science in Clinical Medicine from the same university in 2016. This solid educational background provided Dr. Shen with a comprehensive understanding of clinical medicine, research methodologies, and translational science.

Research Focus

Dr. Shen’s research primarily investigates the interplay between immunometabolism and disease progression, with a special focus on the microenvironmental regulation within atherosclerotic plaques. His work explores innovative approaches such as enzymatic catalysis, nanozyme-based therapies, and multifunctional nanoparticles for targeted modulation of inflammation and cholesterol metabolism. By elucidating how macrophage polarization and metabolic reprogramming influence disease states, Dr. Shen aims to identify novel therapeutic targets and develop advanced nanomedicine platforms to enhance treatment efficacy in cardiovascular and oncological diseases.

Experience

Since 2023, Dr. Shen has held multiple prestigious postdoctoral research positions, including at the National University of Singapore under Professor Xiaoyuan Chen and at Wenzhou Medical University with Professors Xiaokun Li and Jiansong Ji. Beyond research, he actively contributes to clinical administration as the Assistant to the Director of the Orthopedics Department and Deputy Secretary of the Youth League Committee at the Fifth Affiliated Hospital of Wenzhou Medical University. In 2024, he was promoted to Associate Research Fellow at the same hospital, reflecting his growing impact and leadership in both research and clinical spheres.

Research Timeline & Activities

Dr. Shen’s recent projects span from 2024 to 2028 and include funded studies such as the NSFC Young Scientist Fund project on fusion protein-coated vascular stents aimed at anti-restenosis, as well as provincial grants focusing on nano-drug delivery systems and calcium carbonate-based nanoparticles for plaque microenvironment modulation. His research activities encompass molecular imaging, immune microenvironment tracking, and metabolic pathway analysis, leading to numerous publications in high-impact journals. This trajectory illustrates a focused effort to translate molecular insights into clinically relevant interventions.

Awards & Honors

Dr. Shen has been recognized with significant awards and research funding, including the prestigious National Natural Science Foundation of China Young Scientist Fund, multiple China Postdoctoral Science Foundation grants, and Zhejiang provincial scientific awards. These honors validate his innovative contributions to biomedical research, particularly in the areas of nanotechnology-based therapies and immunometabolism. Additionally, his role as a council member of the Hospital Intelligent System Construction Branch underscores his involvement in healthcare innovation beyond the laboratory.

Recent Publications

Among his extensive publication record, Dr. Shen’s 2024 article in ACS Nano, titled “NIR-II Imaging for Tracking the Spatiotemporal Immune Microenvironment in Atherosclerotic Plaques,” represents a landmark study combining advanced near-infrared imaging with immunological insights to monitor plaque progression dynamically. This work has been widely cited for its novel methodology and its implications for early diagnosis and targeted treatment of cardiovascular diseases. Dr. Shen’s research continues to push the boundaries of nanomedicine and immune system modulation.

  • Shen L, Yang Z, Zhong Y, Bi Y, Yu J, Lu Q, Su Y, Chen X, Zhao Z, Shu G, Chen M, Cheng L, Feng L, Lu C, Liu Z, Ji J. Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti-Tumor Immune Response. Advanced Science. 2025 Feb. DOI: 10.1002/advs.202406975.

  • Guo X, Chen X, Ding J, Zhang F, Chen S, Hu X, Fang S, Shen L, Lu C, Zhao Z, et al. Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy. Asian Journal of Pharmaceutical Sciences. 2024. DOI: 10.1016/j.ajps.2024.100905.

  • Du Z, Lan C, Shen L, Tian Z, Hu H, Mei J, Feng Y, Zhai M, Yu J, Liu K, et al. Advances in multimodality imaging and the application of new cardiac imaging technologies for radiation-induced heart disease. iRADIOLOGY. 2024. DOI: 10.1002/ird3.72.

  • Chen M, Shu G, Lv X, Xu X, Lu C, Qiao E, Fang S, Shen L, Zhang N, Wang J, et al. Corrigendum to “HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma”. Biomaterials. 2024. DOI: 10.1016/j.biomaterials.2024.122676.

  • Bi Y, Ying X, Chen W, Wu J, Kong C, Hu W, Fang S, Yu J, Zhai M, Jiang C, et al., Shen L. Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma. Lipids in Health and Disease. 2024. DOI: 10.1186/s12944-024-02298-4.

Strengths for the Best Innovator Award

  1. Pioneering Research in Immunometabolism and Nanomedicine
    Dr. Lin Shen’s innovative work at the interface of immunometabolism and nanotechnology has paved new avenues in treating complex diseases such as atherosclerosis and cancer. His development of nano-drug delivery platforms and catalytic hydrogels showcases his ability to translate cutting-edge science into impactful therapeutic strategies.

  2. Cross-Disciplinary Expertise Bridging Basic and Clinical Sciences
    With a strong foundation in surgery and molecular medicine, Dr. Shen uniquely integrates clinical insights with molecular research. This rare combination enables him to develop solutions that are not only scientifically groundbreaking but also highly relevant to patient care and clinical applications.

  3. Successful Leadership and Collaborative Roles
    Beyond his research, Dr. Shen has taken on significant leadership roles, such as Assistant to the Director in Orthopedics and Deputy Secretary of the Youth League Committee. His ability to foster collaboration across clinical departments and research teams highlights his innovation not only in science but also in organizational development.

  4. Recognition through Prestigious Funding and Awards
    Dr. Shen’s receipt of major grants, including the National Natural Science Foundation of China Young Scientist Fund and multiple postdoctoral awards, validates the originality and potential impact of his research projects. These competitive accolades affirm his status as a leading innovator in biomedical research.

  5. High-Impact Publications with Practical Implications
    Dr. Shen’s research outputs, featured in top-tier journals like Advanced Science and ACS Nano, demonstrate significant advancements in imaging, immune modulation, and therapeutic nanotechnologies. His publications not only advance scientific knowledge but also provide practical methodologies for improving disease diagnosis and treatment.

Sreeraj vasudevan, Medicine, Innovative Researcher Award

Posted on by scizentox scizentoxLeave a Comment on Sreeraj vasudevan, Medicine, Innovative Researcher Award

Assoc. Prof. Sreeraj vasudevan: HOD Clinical Hematology at Amala Institute of Medical Sciences, India

Dr. Sreeraj V is a highly skilled Clinical Hematologist and Assistant Professor with extensive experience in both the clinical and academic spheres. Over the course of his career, Dr. Sreeraj has developed a deep expertise in managing hematological malignancies, including acute myeloid leukemia (AML), lymphoma, multiple myeloma, and myeloproliferative neoplasms. He is particularly recognized for his work in stem cell transplantation and advanced hematology therapies. Currently, Dr. Sreeraj serves as an Assistant Professor in the Department of Medical Oncology and Hematology at Amala Institute of Medical Sciences, Thrissur, Kerala. He has played a pivotal role in establishing the Hematology and Bone Marrow Transplantation Unit at Amala, where he oversees the management of complex hematological cases. His clinical and research focus is centered on improving patient outcomes through innovative treatments and cutting-edge therapies, including CAR-T cell therapy and bispecific antibody therapies for hematologic malignancies. Alongside his clinical work, he is passionate about medical education, mentoring students, and contributing to the development of hematology professionals across the country.

Online Profiles

Dr. Sreeraj Vasudevan is an Associate Professor at Amala Institute of Medical Sciences, Thrissur, India. He has an active Scopus ID (59197095400) and an ORCID profile for research visibility. His work has garnered 3 citations across 4 documents.

Education

Dr. Sreeraj’s academic journey began with his MBBS from Government Medical College, Thrissur, Kerala, followed by an MD in Medicine from Madurai Medical College, Tamil Nadu, one of the leading institutions in India. His passion for hematology led him to pursue a DM (Doctorate of Medicine) in Hematology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi. Throughout his education, he consistently demonstrated an aptitude for clinical excellence and a strong interest in research, particularly in the field of hematological disorders. The culmination of his education prepared him to lead cutting-edge research and clinical teams in both academic and healthcare settings.

Research Focus

Dr. Sreeraj’s research interests are focused on advancing the diagnosis and treatment of hematological diseases. His primary areas of research include the biology and management of lymphoma, acute myeloid leukemia (AML), and multiple myeloma. He is particularly interested in stem cell transplantation, including both autologous and allogeneic transplants, and has contributed to the development of new therapeutic strategies in this area. His research is also directed toward improving the outcomes for patients undergoing CAR-T cell therapy, an area where he has significantly contributed. Additionally, Dr. Sreeraj is engaged in exploring novel treatments for anemia, myelodysplastic syndromes (MDS), and myeloproliferative disorders, all while working on molecular biomarkers for hematological malignancies. His work has led to the publication of several influential papers that have shaped current practices in hematology.

Experience

With over a decade of clinical and academic experience, Dr. Sreeraj has worked across multiple prestigious institutions in India, including AIIMS, CMC Vellore, and Amala Institute of Medical Sciences, Thrissur. His career began with a rotating internship at Government Medical College, Thrissur, and later included a pivotal year as a rural service physician under the National Rural Health Mission (NRHM). Dr. Sreeraj’s clinical expertise expanded as he worked as an Internal Medicine Physician at Almas Hospital in Kerala and as a Non-Academic Resident in Clinical Hematology at CMC Vellore. In 2017, he joined Amala Institute of Medical Sciences, where he has since become a key figure in both patient care and academic training. In his current role as Assistant Professor in the Department of Medical Oncology and Hematology, Dr. Sreeraj supervises both clinical and research operations, with a specific focus on hematological malignancies and stem cell transplantation. He is instrumental in setting up a comprehensive bone marrow transplant unit at Amala, which serves as a vital resource for patients in Kerala.

Research Timeline & Activities

  • 2019-Present: As a lead consultant in Hematology, Dr. Sreeraj initiated and developed a comprehensive bone marrow transplantation program at Amala Institute of Medical Sciences, which includes allogeneic transplants (matched-related, unrelated, and haploidentical) and peripheral blood stem cell harvesting.

  • 2020-2021: Dr. Sreeraj’s team began a detailed investigation into the role of bispecific antibodies in the treatment of multiple myeloma, leading to collaborative research projects with international researchers.

  • 2022-Present: He is now heavily involved in the clinical development and implementation of CAR-T cell therapy at Amala Institute of Medical Sciences, a pioneering program aimed at improving outcomes for patients with refractory hematological cancers.

  • 2023: Dr. Sreeraj’s research into molecular biomarkers in lymphoma and AML has gained recognition at national conferences, contributing to the development of personalized treatment approaches.

  • Ongoing: In addition to his clinical responsibilities, Dr. Sreeraj continues to explore the mechanisms of resistance in AML and lymphoma therapies, collaborating with research institutions to further enhance patient care through targeted therapies.

Awards & Honors

  • Best Researcher Award, AIIMS, New Delhi (2016): Recognized for exceptional research in hematology during his time at AIIMS, particularly in the area of stem cell transplantation.

  • Excellence in Teaching Award, Amala Institute of Medical Sciences, Thrissur (2021): Acknowledged for his dedication to medical education and training the next generation of hematologists, oncologists, and medical professionals.

  • Research Excellence Award, Indian Society of Hematology & Blood Transfusion (2023): Honored for contributions to hematology research, particularly in the areas of lymphoma management and stem cell transplantation.

  • Best Clinical Practice Award, Amrita Institute of Medical Sciences (2019): Recognized for improving clinical protocols and outcomes in hematology patient care.

Top Noted Publication

A specific article titled “Investigation of an Outbreak in a Resource-Limited Setting – Burkholderia cepacia Bloodstream Infection in an Oncology Unit,” which is part of a publication or journal “Reviews and Research in Medical Microbiology” from 2025.

  • Vasudevan, S., Gundarlapalli, S., Thalambedu, N., & Mohan, M. (2022). Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. touchREVIEWS in Oncology & Haematology, 18(1), 59-66. https://doi.org/10.17925/OHR.2022.18.1.59

  • Philip, C., Selvarajan, S., Nayak, L., Jain, H., Kulkarni, U., Samuel, P., Agrawal, N., Kayal, S., Mishra, K., Pavitra, D.S., Jayachandran, P.K., Bala, S.C., Raghavan, V., Paul, M., Singh, J., Vasudevan, S., Mujumdar, S., Nayak, A., Prakash, O., Barath, U., Dharmaraj, A., Rajendra, A., Thorat, J., Bagal, B., Abraham, A., Bhurani, D., Ganesan, P., Sengar, M., & Mathews, V. (2024). Impact of the COVID-19 Pandemic on Treatment of Patients with Acute Myeloid Leukaemia in India. British Journal of Haematology, 205(6), 2058-2062. https://doi.org/10.1111/bjh.19750

  • Singh, S., Lionel, S., Vasudevan, S., Jain, H., et al. (2024). Treatment Challenges and Outcomes of Older Patients with Acute Myeloid Leukemia from India. Annals of Hematology, 103, 4079–4088. https://doi.org/10.1007/s00277-024-05873-y

  • Vasudevan, S., Cyriac, S., Puthillathu, U., Moothiringode Chithrabhanu, S., Aggarwal, S., & Thazhath, A. J. (2022). The Clinical Profile of JAK2 Negative, Normal Erythropoietin, Normal Arterial Oxygen Saturation Erythrocytosis in an Indian Tertiary Centre. Blood, 140(Supplement 1), 12268–12269.

  • Vasudevan, S., Lal, B. M., Vojjala, N., & Mohan, M. (2025). Addressing Practical Challenges with Bispecific Antibody Therapy in Multiple Myeloma. Expert Opinion on Biological Therapy, 25(6), 607–613. https://doi.org/10.1080/14712598.2025.2495984

Innovative Researcher Award Nomination for Dr. Sreeraj Vasudevan

1. Advancing Hematology Treatment with Stem Cell Transplantation and CAR-T Cell Therapy

Dr. Vasudevan has made groundbreaking contributions to hematology, particularly in stem cell transplantation and CAR-T cell therapy for hematological cancers. His leadership in developing the Bone Marrow Transplantation Unit at Amala Institute of Medical Sciences has allowed for the integration of state-of-the-art techniques in hematological care, such as haploidentical and peripheral blood stem cell harvesting. His pioneering role in implementing CAR-T cell therapy in India has significantly impacted patient outcomes in refractory hematologic malignancies, particularly lymphoma and leukemia.

Key Innovation:

  • Developed and implemented advanced stem cell transplantation protocols and CAR-T cell therapy.

  • Significantly improved patient survival rates through personalized and targeted treatments.

2. Targeted Therapeutics: Research on Bispecific Antibodies and Novel Therapies

Dr. Vasudevan’s research into bispecific antibodies as a novel therapeutic strategy for multiple myeloma has resulted in new insights that have reshaped treatment approaches. His work has led to international collaborations and advanced clinical trials, which aim to overcome the challenges posed by traditional therapies.

Key Innovation:

  • Focused on enhancing the effectiveness of bispecific antibody therapies to improve treatment for refractory multiple myeloma.

  • Contributed to a deeper understanding of the challenges and opportunities with bispecific antibody therapies in real-world clinical settings.

3. Molecular Biomarkers and Personalized Medicine in Hematology

His pioneering research into molecular biomarkers for hematologic cancers, such as acute myeloid leukemia (AML) and lymphoma, is enabling more accurate diagnosis and personalized treatment strategies. Dr. Vasudevan’s work aims to identify biomarkers that predict patient responses to therapies, allowing for the development of more targeted and individualized treatment plans, ultimately improving patient outcomes.

Key Innovation:

  • Pioneering work on biomarker discovery that facilitates personalized therapies in AML, lymphoma, and other hematological disorders.

  • Spearheaded efforts to understand mechanisms of treatment resistance, thereby contributing to the development of second-line therapies.

4. Leadership in Medical Education and Mentorship

As an Assistant Professor in the Department of Medical Oncology and Hematology, Dr. Vasudevan has fostered the development of future generations of hematologists and oncologists. His innovative teaching methods and commitment to integrating the latest research into academic curricula have ensured that young doctors are well-versed in emerging therapies and clinical practices.

Key Innovation:

  • Integration of cutting-edge research into medical curricula for the next generation of hematologists.

  • Active mentorship and training programs that are molding future leaders in hematology and oncology.

5. Clinical Leadership and Impact During COVID-19

Dr. Vasudevan played a vital role in adapting clinical practices during the COVID-19 pandemic, with particular focus on hematology patients. His research into the impact of COVID-19 on the treatment of acute myeloid leukemia (AML) patients in India, highlighted in journals such as the British Journal of Haematology, has significantly influenced clinical guidelines for treating hematologic cancer patients during global health crises.

Key Innovation:

  • Conducted pivotal research on COVID-19 and hematological malignancies, leading to changes in treatment protocols for AML patients during the pandemic.

  • Helped shape national treatment strategies and ensure continued care for immunocompromised patients in the midst of the crisis.

Srivalli Chilakamarri, Medicine, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Srivalli Chilakamarri, Medicine, Best Innovator Award

Dr. Srivalli Chilakamarri: Consultant, Otorhinolaryngology & Head and Neck Surgery at Independent Practitioner, India

Title/Designation: Dr
Name: Srivalli Chilakamarri
Current Role/Designation: Consultant, Otorhinolaryngology & Head and Neck Surgery
Organization/Institution: Independent Practitioner, India
Subject Track: Medicine
Key Areas of Expertise: Otorhinolaryngology & Head and Neck Surgery
Award Category: Best Innovator Award

Dr. Srivalli Chilakamarri is a Consultant in Otorhinolaryngology and Head & Neck Surgery, with a dedicated focus on Head & Neck Oncosurgery. She is trained in the surgical management of complex ENT and head and neck conditions and combines her clinical expertise with a strong passion for medical research. Her work emphasizes evidence-based care, patient-centered treatment, and academic rigor. She has authored multiple publications in indexed journals, actively participates in national and international conferences, and is committed to advancing surgical techniques and improving patient outcomes in head and neck oncology.

Online Profiles

ORCID Profile

Education

She completed her Master of Surgery (MS) in Otorhinolaryngology & Head & Neck Surgery at Indira Gandhi Medical College & Research Institute, Puducherry (2022–2025), graduating as Institute Topper. Prior to this, she earned her MBBS from Mahatma Gandhi Medical College & Research Institute, Puducherry (2013–2019), where she was awarded the Gold Medal for outstanding academic performance. Her educational journey reflects both excellence in theoretical knowledge and proficiency in surgical skills, laying a strong foundation for her clinical and research career.

Research Focus

Dr. Chilakamarri’s research centers on advancing clinical knowledge and surgical practices in head and neck oncology, pediatric otitis media, and rare ENT pathologies. She has conducted studies on caregiver knowledge, attitudes, and practices in pediatric ENT conditions, documented unusual ENT tumors, and investigated innovative approaches to improve visualization and outcomes in middle ear surgery. Her work integrates clinical research, case studies, and epidemiological investigations to inform evidence-based interventions and improve patient care quality.

Experience

With hands-on expertise in endoscopic and microscopic ear surgery, functional endoscopic sinus surgery (FESS), septoplasty, adenotonsillectomy, thyroidectomy, and management of rare ENT tumors, Dr. Chilakamarri has extensive clinical experience in complex surgical procedures. She combines this with her role as a medical researcher, contributing to peer-reviewed publications, mentoring trainees, presenting at conferences, and reviewing manuscripts for international journals. Her experience reflects a balance of surgical precision, academic research, and commitment to patient-centered care.

Research Timeline & Activities

Dr. Chilakamarri’s research activities span clinical studies, case reports, and cross-sectional surveys conducted between 2023 and 2025. Key projects include studying unilateral sinonasal masses, managing rare cricotracheal separations, evaluating allergic rhinitis in medical students, investigating caregiver burnout in head and neck cancer, and exploring laryngeal transplantation. She has actively presented her findings in national and international conferences, including TNAOI conclaves and international webinars, demonstrating a strong commitment to academic dissemination and collaborative research.

Awards & Honors

  • Institute Topper, MS (Otorhinolaryngology & HNS), Indira Gandhi Medical College & Research Institute, 2025

  • Gold Medalist, MBBS, Mahatma Gandhi Medical College & Research Institute, 2019

  • Recognition for multiple oral and poster presentations at AOI and international webinars (2023–2025)

  • Selected to review manuscripts for leading journals, reflecting academic credibility and professional recognition in ENT research

Top Noted Publications

  1. From Reflection to Detection: Leveraging Mirror Checks to Tackle India’s Oral Cancer Burden
    Indian Journal of Otolaryngology and Head & Neck Surgery, 2025-09-01.
    DOI: 10.1007/s12070-025-06032-z
    Contributors: Srivalli Chilakamarri, Aarthi Natarajan, Aman Prakash

  • Focuses on early detection strategies for oral cancer in India using simple mirror check techniques to empower patients and caregivers.

  1. Held Hands and Healing: What My Patient Taught Me During Residency
    Journal of Cancer Education, 2025-08-11.
    DOI: 10.1007/s13187-025-02707-x
    Contributors: Srivalli Chilakamarri

  • Reflective piece emphasizing the patient-doctor relationship and its impact on learning and compassionate care during residency.

  1. Malignant Otitis Externa and Atypical Skull Base Osteomyelitis
    Bengal Journal of Otolaryngology and Head Neck Surgery, 2025-08-02.
    DOI: 10.47210/bjohns.2024.v32i3.204
    Contributors: Aarthi Gopal, Sophia Amalanathan, Srivalli Chilakamarri, Kumaran Ramesh Colbert, Satish Kumar C

  • Clinical study detailing complex cases of malignant otitis externa and unusual skull base osteomyelitis, highlighting diagnostic and therapeutic challenges.

  1. Asymmetrical tonsil: A case report
    Journal of Indira Gandhi Institute of Medical Sciences, 2025-06-25.
    DOI: 10.4103/jigims.jigims_43_24
    Contributors: Srivalli Chilakamarri, Kumaran Ramesh Colbert, Satish Kumar Chockalingam, C. S Banushree, Sophia Amalanathan

  • Case report on a rare asymmetrical tonsillar presentation, contributing to the literature on differential diagnosis and management.

  1. Developing and validating Questionnaire for Knowledge, Attitude and Practices among the caretakers for Risk factors in Otitis media (RFOMQ-24) in children
    European Archives of Oto-Rhino-Laryngology, 2025-05.
    DOI: 10.1007/s00405-024-09099-6
    Contributors: Sophia Amalanathan, Srivalli Chilakamarri, Kumaran Ramesh Colbert, C. Satish Kumar

  • Development and validation of a structured questionnaire assessing caregiver knowledge and practices related to pediatric otitis media risk factors.

Strength for the Best Innovator Award

1. Pioneering Research in Head & Neck Oncology

Dr. Chilakamarri has contributed original research addressing critical gaps in early detection and management of head and neck cancers in India, such as the use of mirror checks for oral cancer detection. Her work demonstrates innovative approaches that combine clinical practicality with evidence-based methodology, reflecting a commitment to improving patient outcomes through novel strategies.

2. Clinical Innovation in Complex ENT Surgery

With hands-on expertise in advanced procedures including endoscopic and microscopic ear surgery, FESS, and rare ENT tumor management, she continuously integrates surgical innovation into practice. Her efforts to optimize visualization and outcomes in chronic otitis media and other complex conditions showcase her ability to translate research into practical, patient-centered solutions.

3. Development of Evidence-Based Tools for Caregivers

She has developed and validated structured questionnaires to assess caregiver knowledge, attitudes, and practices in pediatric otitis media (RFOMQ-24). This reflects her innovative contribution to preventive healthcare and education, creating tools that can guide policy and improve awareness at the community level.

4. Commitment to Academic Excellence and Knowledge Dissemination

Dr. Chilakamarri actively participates in national and international conferences, presenting both oral and poster presentations, and serves as a reviewer for high-impact journals. Her proactive dissemination of research findings demonstrates leadership in advancing ENT and head & neck oncology knowledge and inspiring other clinicians and researchers.

5. Integrating Research, Reflection, and Compassion in Medical Practice

Through reflective pieces such as Held Hands and Healing, she bridges clinical innovation with empathetic patient care. This combination of scientific rigor and humanistic practice highlights her holistic approach to medical innovation, ensuring that advancements benefit both the medical community and the patients directly.